SEC Form 4 · accession 0001282930-26-000008
BlossomHill Therapeutics, Inc. · BLSM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Carl L Gordon
Director
Period of report
Aug 6, 2026
Accepted (ET)
Aug 10, 2026 · 6:33 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001839970
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Director Stock Option (Right to Buy)F2,F1 | $16.00 | Aug 6, 2026 | A | 23,904 | A | — | Aug 5, 2036 | Common Stock | 23,904 | 23,904 | D |
Explanation of responses
- F11/36th of the shares subject to the option shall vest in equal monthly installments over a three year period following August 6, 2026.
- F2Pursuant to an agreement with OrbiMed Advisors LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof to OrbiMed Advisors LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments VIII, LP.